SLC5A2 and hydrops fetalis: According to more recent data, SGLT-2 inhibitors are no longer considered purely anti-diabetic drugs, as they have now received an indication for administration to patients with heart failure (HF) and chronic kidney disease (CKD), regardless of the presence of diabetes mellitus [8].